Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-α blocking agents

Journal of the European Academy of Dermatology and Venereology

Volumn 23, Issue 8, 2009, Pages 967-968

  Lourari, S ^a   Prey, S ^a   Livideanu, C ^a   Jamard, B ^b   Lamant, L ^c   Cantagrel, A ^b   Paul, C ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b CHU RANGUEIL   (France)

^c CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; CASE REPORT; DISEASE ASSOCIATION; FEMALE; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN LYMPHOMA; T CELL LYMPHOMA;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; LYMPHOMA, T-CELL, CUTANEOUS; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67651176200     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2008.03074.x     Document Type: Letter

References (10)

1. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002 46 : 3151 3158.
2. Flendrie M, Vissers WH, Creemers MC, de Jong EM et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005 7 : R666 R676. Epub 2005 Apr 4.
3. Dalle S, Balme B, Berger F, Hayette S, Thomas L. Mycosis fongoides-associated follicular mucinosis under Adalimumab. Br J Dermatol 2005 153 : 207 208.
4. + cutaneous T-cell lymphoma after immunomodulatory therapy. Clin Lymphoma Myeloma 2006 6.
5. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 295 : 2275 2285.
6. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, AL. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005 64 : 1421 1426. (Pubitemid 41623851)
7. Dauendorffer JN, Rivet J, Allard A, Bachelez H. Sézary syndrome in a patient receiving infliximab for ankylosing spondylitis. Br J Dermatol 2007 156 : 742 743.
8. Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR et al. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. JAAD 2004 51 : 660 662.
9. + T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003 149 : 170 173.
10. Sanli H, Ataman S, Akay BN, Yilmaz A, Yildizlar D, Gürgey E. Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy. J Drugs Dermatol 2007 6 : 834 836.